[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation
- PMID: 33772334
- PMCID: PMC8440288
- DOI: 10.1007/s00259-021-05303-5
[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation
Erratum in
-
Correction to: [18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation.Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3745-3746. doi: 10.1007/s00259-021-05397-x. Eur J Nucl Med Mol Imaging. 2021. PMID: 34037832 Free PMC article. No abstract available.
Abstract
Purpose: To test the performances of native and tumour to liver ratio (TLR) radiomic features extracted from pre-treatment 2-[18F] fluoro-2-deoxy-D-glucose ([18F]FDG) PET/CT and combined with machine learning (ML) for predicting cancer recurrence in patients with locally advanced cervical cancer (LACC).
Methods: One hundred fifty-eight patients with LACC from multiple centers were retrospectively included in the study. Tumours were segmented using the Fuzzy Local Adaptive Bayesian (FLAB) algorithm. Radiomic features were extracted from the tumours and from regions drawn over the normal liver. Cox proportional hazard model was used to test statistical significance of clinical and radiomic features. Fivefold cross validation was used to tune the number of features. Seven different feature selection methods and four classifiers were tested. The models with the selected features were trained using bootstrapping and tested in data from each scanner independently. Reproducibility of radiomics features, clinical data added value and effect of ComBat-based harmonisation were evaluated across scanners.
Results: After a median follow-up of 23 months, 29% of the patients recurred. No individual radiomic or clinical features were significantly associated with cancer recurrence. The best model was obtained using 10 TLR features combined with clinical information. The area under the curve (AUC), F1-score, precision and recall were respectively 0.78 (0.67-0.88), 0.49 (0.25-0.67), 0.42 (0.25-0.60) and 0.63 (0.20-0.80). ComBat did not improve the predictive performance of the best models. Both the TLR and the native models performance varied across scanners used in the test set.
Conclusion: [18F]FDG PET radiomic features combined with ML add relevant information to the standard clinical parameters in terms of LACC patient's outcome but remain subject to variability across PET/CT devices.
Keywords: Cervical cancer; Disease-free survival; Machine learning; Radiomics; [18F]FDG PET/CT.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Dr. Philippe Lambin reports, within and outside the submitted work, grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic/DNAmito, Health Innovation Ventures. He received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind manpower contribution from Oncoradiomics, BHV, Merck, Varian, Elekta, ptTheragnostic and Convert pharmaceuticals. Dr. Lambin has shares in the company Oncoradiomics, Convert pharmaceuticals, MedC2 and LivingMed Biotech; he is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patented invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures and three non-issues, non licensed patents on Deep Learning-Radiomics and LSRT (N2024482, N2024889, N2024889). He confirms that none of the above entities or funding was involved in the preparation of this paper.
Figures



References
-
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer. 2012:2015. 10.1002/ijc.29210. - PubMed
-
- Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie-Meder C, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Virchows Arch an Int J Pathol. 2018. 10.1007/s00428-018-2380-7. - PubMed
-
- Marth C, Landoni F, Mahner S, Mccormack M, Colombo N. Cervical cancer : ESMO Clinical Practice Guidelines for Clinical Practice Guidelines. Ann Oncol. 2017. 10.1093/annonc/mdx220. - PubMed
-
- Gandy N, Arshad MA, Park WHE, Rockall AG, Barwick TD. FDG-PET imaging in cervical cancer. Semin Nucl Med. 2019; 10.1053/j.semnuclmed.2019.06.007 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical